Impact of Nrf2 expression in reconstituting T-cells of allogeneic hematopoietic stem cell transplanted patients
Franziska Karl(Friedrich-Alexander-Universität Erlangen-Nürnberg), Dimitrios Mougiakakos(Otto-von-Guericke-Universität Magdeburg), Wolf Rösler, Rebecca Baur(Friedrich-Alexander-Universität Erlangen-Nürnberg), Regina Jitschin(Friedrich-Alexander-Universität Erlangen-Nürnberg), Romy Loschinski(Otto-von-Guericke-Universität Magdeburg), Simon Völkl(Universitätsklinikum Erlangen), Andréas Mackensen(University Medical Center Freiburg), Martin Böttcher(Otto-von-Guericke-Universität Magdeburg), Andrej Stoll(Friedrich-Alexander-Universität Erlangen-Nürnberg), Bénédikt Jacobs(Oslo University Hospital)
Cited by 9
Related Papers
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
|The Lancet Oncology|2015|402
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
|The Lancet Haematology|2019|247
The complement system drives local inflammatory tissue priming by metabolic reprogramming of synovial fibroblasts
|Immunity|2021|245
Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells
|Cancer Immunology Immunotherapy|2000|240